Extended-release naltrexone and buprenorphine/naloxone are similarly efficacious in preventing relapse for patients with opioid use disorder, although naltrexone was more difficult to initiate.Medscape Medical News (Source: Medscape Medical News Headlines)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

{ 0 comments }

WAREHAM (CBS) – One out of every four teenagers admits to misusing or abusing, a prescription drug.
It’s a dangerous road that can lead to addiction. To prevent and treat drug-use in kids there is now a first-of-its-kind program tackling the issue head-on right at the pediatrician’s office.
At Wareham Pediatrics, the Cat in the Hat welcomes young patients and route markers provide a guide to the exam rooms.
(WBZ-TV)
But the practice itself could be creating a road map to prevent and treat addiction in kids.
(WBZ-TV)
“It was a really helpless feeling to sometimes see kids and families struggling with drug, alcohol, or even worse opiate use and not have the tools,” Dr. Jason Reynolds told WBZ-TV.
Wareham Pediatrics now has those tools.
It is believed to be the o…

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

{ 0 comments }

Opioid treatment drugs have similar outcomes once patients initiate treatment

November 16, 2017

NIDA study compares buprenorphine/naloxone combination to extended release naltrexone. (Source: National Institutes of Health (NIH) News Releases)

Read the full article →

Study: Head-to-head comparison of opioid use disorder therapies finds similarities

November 16, 2017

A study published today in The Lancet found that two different therapies used to treat opioid use disorder – an extended-release naltrexone injection and a combination of buprenorphine and naloxone – have similar outcomes once patients get past the hurdle of starting treatment. This is the first study to compare the combination therapy and naltrexone head-to-head in […]

Read the full article →

Opioid Addiction Treatments Face Off in US Trial

November 16, 2017

CHICAGO (AP) — The first U.S. study to compare two treatments for opioid addiction finds a monthly shot works as well as a daily drug to prevent relapse. The shot requires days of detox first and that proved to be a stumbling block for many. For those who made it past that hurdle, the shot […]

Read the full article →

Extended-Release Naltrexone Seems as Effective as Standard Treatment for Opioid Dependence (FREE)

October 20, 2017

By Amy Orciari Herman Edited by Susan Sadoughi, MD Injectable extended-release naltrexone (Vivitrol) appears to be as safe and effective as daily oral buprenorphine-naloxone for treating opioid dependence, according to a Norway-based, noninferiority trial … (Source: Physician’s First Watch current issue)

Read the full article →

Opioid Blocker as Good as Suboxone in First Head-to-Head Trial (CME/CE)

October 20, 2017

(MedPage Today) — Monthly naltrexone (Vivitrol) non-inferior to buprenorphine/naloxone (Source: MedPage Today Pain Management) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read the full article →

CHMP Backs Two Drugs for Opioid Abuse CHMP Backs Two Drugs for Opioid Abuse

September 16, 2017

The EMA committee recommends naloxone nasal spray (Nyxoid) for treatment of opioid overdose and buprenorphine plus naloxone sublingual tablets (Zubsolv) for treatment of opioid dependence.International Approvals (Source: Medscape Medical News Headlines) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read the full article →

Addressing stigma in medication treatment of adolescents with opioid use disorder – Bagley SM, Hadland SE, Carney BL, Saitz R.

August 8, 2017

: In September 2016, the American Academic of Pediatrics released a policy statement that adolescents with opioid use disorder should be offered pharmacotherapy with buprenorphine/naloxone, methadone, or naltrexone. In our clinical practice, however, we ha… (Source: SafetyLit) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your […]

Read the full article →

Rapid Growth in Medicaid Spending on Medications to Treat Opioid Use Disorder and Overdose (June 2017)

July 17, 2017

Report used state Medicaid drug utilization files from 2011 to 2016 to assess spending on buprenorphine, naltrexone, and naloxone prescriptions. (Source: HSR Information Central) MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Read the full article →